European Commission approves BMS' ORENCIA for methotrexate-naive RA patients
The European Commission has approved Bristol-Myers Squibb’s ORENCIA (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, in combination with methotrexate (MTX), for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis (RA) not previously treated with MTX.
With this approval, ORENCIA is the first biologic therapy with an indication in the European Union (EU) specifically applicable to the treatment of MTX-naive RA patients with highly active and progressive disease.
Click on this link for more information.
